Hiv Fusion Articles & Analysis
2 news found
Anastasia Batrak, Vice President of strategic marketing and product portfolio development at R-Pharm, said, “The drug-resistant strains of HIV are a serious threat to public safety. In Russia, 6-7% of newly treated patients have HIV resistance. ...
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: ...